TRVI
Trevi Therapeutics Inc
Halal Rating :
Last Price
$3.77
Last updated:
Market Cap
-
7D Change
-5.51%
1 Year Change
187.79%
Company Overview
Industries
Exchange
Next Earnings Date
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for neurologically mediated conditions including chronic pruritus and chronic cough. Their lead product candidate is Haduvio (nalbuphine ER), which is being developed for the treatment of chronic pruritus, chronic cough in idiopathic pulmonary fibrosis (IPF), and other neurologically mediated conditions.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Trevi Therapeutics Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.